#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
Children’s Hospital Boston is home to the world’s most extensive research enterprise at a pediatric hospital, and our research informs our treatments.
Children’s researcher Narayanaswamy Ramesh, PhD, conducts molecular studies on primary immunodeficiencies. Eventually his studies may lead to the development of a molecular framework for testing chemicals as potential therapeutic drugs. The immediate goals of his research are to:
His recent investigations have focused on Wiskott-Aldrich syndrome (WAS), which is caused by mutation in the gene encoding for the WAS protein (WASP). Dr. Ramesh and colleagues have been interested in the role of WASP on the cytoskeleton—the cell's dynamic structural framework—which is composed of the protein actin and non muscle myosin. WASP is known to have a role in cytoskeletal remodeling, which is essential to immune-cell functions, such as activation and motion.
Recently, his laboratory identified a novel cellular protein that acts as a negative regulator of WASP. The researchers have demonstrated that the protein, which they have named WIP, acts with WASP to regulate cytoskeletal remodeling during immune-cell activation. WIP is multifunctional, acting as a molecular scaffold and linking a cellular signaling pathway(s) to actin in cytoskeletal remodeling. They are now studying the role of WASP and WIP in immune cell functions that require active cytoskeletal remodeling, such as chemotaxis, homing, and molecular events triggered by cell-cell and cell-matrix interaction.
Wiskott Aldrich Syndrome (WAS) is a rare primary immune deficiency disease causing significant bleeding due to low platelet count and increased incidence of serious infections.Platelet cells are cells found in the blood that help control bleeding. Read more on how Children's has partnered with Genethon of France, to get FDA approval for a Wiskott Aldrich gene therapy trial.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”